1. Home
  2. TK vs XERS Comparison

TK vs XERS Comparison

Compare TK & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teekay Corporation

TK

Teekay Corporation

HOLD

Current Price

$14.14

Market Cap

937.1M

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.23

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TK
XERS
Founded
1973
2005
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
937.1M
1.0B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
TK
XERS
Price
$14.14
$6.23
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$10.83
AVG Volume (30 Days)
453.0K
1.6M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
15.21%
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.01
Revenue
N/A
$49,590,000.00
Revenue This Year
N/A
$34.37
Revenue Next Year
N/A
$22.86
P/E Ratio
$13.43
$590.00
Revenue Growth
N/A
142.67
52 Week Low
$7.12
$4.30
52 Week High
$14.38
$10.08

Technical Indicators

Market Signals
Indicator
TK
XERS
Relative Strength Index (RSI) 62.67 50.83
Support Level $12.09 $5.79
Resistance Level $14.38 $6.41
Average True Range (ATR) 0.53 0.31
MACD -0.03 -0.04
Stochastic Oscillator 83.44 31.49

Price Performance

Historical Comparison
TK
XERS

About TK Teekay Corporation

Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: